Richard Hughes, Member of the Firm, speaks on a panel, “Vaccine Innovation and the Future of Life-Course Immunization,” at the 2022 International Convention, hosted by Biotechnology Innovation Organization (BIO).
The COVID-19 pandemic has been a catalyst for vaccine innovation, with both the development of several new vaccines and the advancement of underlying technology platforms that will further accelerate the vaccine pipeline. However, both COVID-19 and routine immunization rates across the life-course remain below domestic and international targets. This panel explores how domestic, regional, and global life-course immunization strategies may be advanced using lessons learned during the ongoing pandemic, in order to (1) address rising vaccine hesitancy; (2) expand supply chain capabilities; (3) ensure equitable access to vaccines and vaccination services; (4) leverage public-private partnerships (PPPs) to drive innovation and expand access; (5) revisit regulatory approaches and pathways for both approvals and reimbursement; and (6) empower all providers in the “immunization neighborhood” to respond to emerging life-course immunization challenges. It applies a comprehensive view of policy, market access, healthcare delivery, public/private partnership, and manufacturing considerations to the current vaccines ecosystem. Attendees will learn practical insights from diverse stakeholders who have been at the forefront of ongoing vaccines innovation opportunities and challenges.
For more information and to register, please visit BIO.org.